<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02948387</url>
  </required_header>
  <id_info>
    <org_study_id>TEF-IT-40A</org_study_id>
    <nct_id>NCT02948387</nct_id>
  </id_info>
  <brief_title>Preventing Infections in Orthopaedic Patients</brief_title>
  <official_title>Antibiotic Prophylaxis for Type II and III Open Fractures: a Retrospective Chart Review</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Olayemi Osiyemi MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Forest Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Triple O Research Institute PA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Determine if antibiotic prophylaxis with intravenous cephalosporin and aminoglycoside in
      patients with Type II and II open fractures is safe and effective.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Determine the safety and efficacy of antibiotic prophylaxis in type II and II open
           fractures when using IV Cephalosporin and aminoglycoside.

        2. Identify the incidence of acute kidney injury.

        3. Identify the type and number of associated infections

        4. Identify the antibiotic resistance profile noted

        5. Identify any secondary infections at sites other than the fracture site
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">February 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of fracture site infections</measure>
    <time_frame>30 days</time_frame>
    <description>number of infections</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of acute renal injury</measure>
    <time_frame>30 days</time_frame>
    <description>number of patients with worsening renal function from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>type of bacteria infection</measure>
    <time_frame>30 days</time_frame>
    <description>name of bacteria infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>resistance trend in patients with infections</measure>
    <time_frame>30 days</time_frame>
    <description>describe the number of MDRO infections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of secondary infections at site other than fracture sites</measure>
    <time_frame>30 days</time_frame>
    <description>describe the number infections at secondary sites</description>
  </secondary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Open Fracture</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who are at least 18 years of age with Type II or III open fractures
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or Female &gt;= 18 years old

          -  Patients are diagnosed with a Type II or III open fracture

        Exclusion Criteria:

          -  Prior to treatment, report of an allergy to beta-lactam or aminoglycoside antibiotics

          -  pregnancy

          -  did not receive 72 hours of IV antibiotic prophylaxis with 1st or 2nd generation
             cephalosporin and either gentamicin or tobramycin

          -  receiving ongoing inpatient care
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olayemi Osiyemi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Triple O Research Institute PA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Paul Glickman</last_name>
    <phone>561-855-7871</phone>
    <email>pglickmn@tripleoresearch.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Olayemi Osiyemi, MD</last_name>
    <phone>561-855-7871</phone>
    <email>drtripleo@tripleoresearch.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Triple O Research Institute PA</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 14, 2016</study_first_submitted>
  <study_first_submitted_qc>October 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2016</study_first_posted>
  <last_update_submitted>October 26, 2016</last_update_submitted>
  <last_update_submitted_qc>October 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Triple O Research Institute PA</investigator_affiliation>
    <investigator_full_name>Olayemi Osiyemi MD</investigator_full_name>
    <investigator_title>President</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fractures, Open</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

